Targeted metagenomic sequencing for all upper respiratory viruses

Through the Innovation Solutions Canada call, the Canadian Government called for testing solutions that could help the country better detect and prevent pandemics. Fusion Genomics accepted this challenge and developed the ONETest Coronaviruses Plus Assay: a genomic-capture assay to accurately and unambiguously diagnose human and animal coronaviruses, as well as all known upper-respiratory viruses. The ONETest Coronaviruses Plus Assay is based on Fusion Genomics’ proprietary ONETest platform, a comprehensive, novel genomic diagnostics platform. When deployed, this assay can warn medical professionals and public health officials about a potential second wave of SARS-CoV-2/COVID-19 (and other zoonotic pathogens) to detect any emerging and re-emerging viruses.

Canada’s National Center for Foreign Animal Diseases (NCFAD) will also use Fusion Genomics’ ONETest Coronaviruses Plus Assay to maintain surveillance of various wild and domestic animals for SARS-CoV-2. This is critical to secure the Canadian food-supply chain.

Fusion Genomics has also completed all proof-of-concept studies for its ONETest RAPID assay, a faster version of the ONETest Coronaviruses Plus Assay that delivers sample-to-sequencing in two hours.

Please contact us if you would like more information about using the ONETest Coronaviruses Plus Assay or the ONETest RAPID Assay in your organization.